Another clinical trial investigated the role of the HIV protease inhibitor nelfinavir in combination with the current standards of care, temozolomide (TMZ) and radiotherapy, based on data that nelfinavir prevents the growth of cancer cell lines by inhibiting the PI3K/Akt/mTOR pathway [38,39]. Here, AKT1 is linked to cancer.